Gilead’s FXR Agonist Posts Questionable Results In NASH, But Offers Hope In PSC

Although GS-9674’s efficacy data don’t appear as promising as that for Intercept’s competing FXR agonist OCA, Gilead seems to be building an argument that its drug has a better combination of efficacy and safety.